Search Results

There are 10101 results for: content related to: Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma

  1. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice

    Fundamental & Clinical Pharmacology

    Volume 28, Issue 6, December 2014, Pages: 652–660, Céline Chu, Chadi Abbara, Mahamadou Tandia, Mélanie Polrot, Patrick Gonin, Robert Farinotti and Laurence Bonhomme-Faivre

    Version of Record online : 16 APR 2014, DOI: 10.1111/fcp.12071

  2. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure

    The Journal of Clinical Pharmacology

    Volume 55, Issue 11, November 2015, Pages: 1303–1312, Alexander K. Berg, Jan C. Buckner, Evanthia Galanis, Kurt A. Jaeckle, Matthew M. Ames and Joel M. Reid

    Version of Record online : 26 JUN 2015, DOI: 10.1002/jcph.543

  3. You have full text access to this OnlineOpen article
    Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo

    Cancer Medicine

    Volume 4, Issue 9, September 2015, Pages: 1309–1321, Joanna P. Wood, Andrew J. O. Smith, Karen J. Bowman, Anne L. Thomas and George D. D. Jones

    Version of Record online : 23 JUN 2015, DOI: 10.1002/cam4.477

  4. Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor

    Biopharmaceutics & Drug Disposition

    Accepted manuscript online: 16 FEB 2017, Emilie Hénin, Mylène Honorat, Jérôme Guitton, Attilio Di Pietro, Léa Payen and Michel Tod

    DOI: 10.1002/bdd.2069

  5. The Role of SN-38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity

    The Journal of Clinical Pharmacology

    Volume 47, Issue 1, January 2007, Pages: 78–86, Dr Roshni P. Ramchandani, Dr Yaning Wang, Dr Brian P. Booth, Dr Amna Ibrahim, Dr John R. Johnson, Dr Atiqur Rahman, Dr Mehul Mehta, Dr Federico Innocenti, Dr Mark J. Ratain and Dr Jogarao V. S. Gobburu

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270006295060

  6. You have free access to this content
    Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors

    Cancer

    Volume 115, Issue 1, 1 January 2009, Pages: 207–216, Adam S. Levy, Paul A. Meyers, Leonard H. Wexler, Regina Jakacki, Anne Angiolillo, Sarah N. Ringuette, Marvin B. Cohen, Richard Gorlick and Other site principal investigators: Wayne Furman, MD (St. Jude Children's Research Hospital, Memphis, Tennessee); Rochelle Bagatell, MD (University of Arizona Health Sciences Center, Tucson, Arizona); Lori Luchtman-Jones, MD (Washington University School of Medicine, St. Louis, Missouri); Luis Eduardo Garcia, MD (Hospital CIMA, San Jose, Costa Rica); and Eric Sandler, MD (Nemours Children's Clinic, Jacksonville, Florida).

    Version of Record online : 17 DEC 2008, DOI: 10.1002/cncr.23992

  7. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital

    Clinical Pharmacology & Therapeutics

    Volume 76, Issue 5, November 2004, Pages: 490–502, Federico Innocenti, Samir D. Undevia, Jacqueline Ramírez, Sridhar Mani, Richard L. Schilsky, Nicholas J. Vogelzang, Marisol Prado and Mark J. Ratain

    Version of Record online : 14 NOV 2004, DOI: 10.1016/j.clpt.2004.07.016

  8. Renal Function as a Predictor of Irinotecan-induced Neutropenia

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 2, August 2008, Pages: 254–262, FA de Jong, JM van der Bol, RHJ Mathijssen, T van Gelder, EAC Wiemer, A Sparreboom and J Verweij

    Version of Record online : 20 FEB 2008, DOI: 10.1038/sj.clpt.6100513

  9. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice

    Fundamental & Clinical Pharmacology

    Volume 29, Issue 3, June 2015, Pages: 219–237, Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Fabienne Thomas, Sylvie Quaranta, Nicolas Picard, Marie-Anne Loriot, Céline Narjoz, Delphine Poncet, Marie-Claude Gagnieu, Cécile Ged, Franck Broly, Valérie Le Morvan, Régis Bouquié, Marie-Pierre Gaub, Laurent Philibert, François Ghiringhelli, Chantal Le Guellec and Collective work by the Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer) and the French Réseau National de Pharmacogénétique Hospitalière (RNPGx)

    Version of Record online : 4 MAY 2015, DOI: 10.1111/fcp.12117

  10. Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver

    Journal of Pharmaceutical Sciences

    Volume 90, Issue 6, June 2001, Pages: 722–731, Christian Farabos, Marie-Christine Haaz, Pierre Gires and Jacques Robert

    Version of Record online : 8 MAY 2001, DOI: 10.1002/jps.1028

  11. You have free access to this content
    Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan

    British Journal of Pharmacology

    Volume 132, Issue 1, January 2001, Pages: 73–84, Corrado Blandizzi, Barbara De Paolis, Rocchina Colucci, Gloria Lazzeri, Fabio Baschiera and Mario Del Tacca

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0703766

  12. You have free access to this content
    Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy

    Cancer

    Volume 97, Issue S9, 1 May 2003, Pages: 2374–2380, Amar Gajjar, Murali M. Chintagumpala, Daniel C. Bowers, Dana Jones-Wallace, Clinton F. Stewart and Kristine R. Crews

    Version of Record online : 17 APR 2003, DOI: 10.1002/cncr.11308

  13. You have free access to this content
    Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice

    British Journal of Pharmacology

    Volume 173, Issue 5, March 2016, Pages: 804–814, Sander A Huisman, Peter de Bruijn, Inge M Ghobadi Moghaddam-Helmantel, Jan N M IJzermans, Erik A C Wiemer, Ron H J Mathijssen and Ron W F de Bruin

    Version of Record online : 8 FEB 2016, DOI: 10.1111/bph.13317

  14. You have full text access to this Open Access content
    Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer

    Cancer Science

    Volume 101, Issue 12, December 2010, Pages: 2591–2595, Hitoshi Kusaba, Taito Esaki, Kitaro Futami, Sinnosuke Tanaka, Hiromitsu Fujishima, Kenji Mitsugi, Kenji Sakai, Hiroshi Ariyama, Risa Tanaka, Naoko Kinugawa, Takashi Ueki, Rhuichi Mibu, Eishi Baba, Shuji Nakano and Koichi Akashi

    Version of Record online : 24 SEP 2010, DOI: 10.1111/j.1349-7006.2010.01728.x

  15. You have free access to this content
    Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer

    British Journal of Clinical Pharmacology

    Volume 59, Issue 4, April 2005, Pages: 415–424, Qingyu Zhou, Alex Sparreboom, Eng-Huat Tan, Yin-Bun Cheung, Ann Lee, Donald Poon, Edmund J. D. Lee and Balram Chowbay

    Version of Record online : 9 FEB 2005, DOI: 10.1111/j.1365-2125.2004.02330.x

  16. You have full text access to this Open Access content
    Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms

    Cancer Science

    Volume 102, Issue 10, October 2011, Pages: 1868–1873, Taroh Satoh, Takashi Ura, Yasuhide Yamada, Kentaro Yamazaki, Toshimasa Tsujinaka, Masaki Munakata, Tomohiro Nishina, Shu Okamura, Taito Esaki, Yasutsuna Sasaki, Wasaburo Koizumi, Yoshihiro Kakeji, Naoki Ishizuka, Ichinosuke Hyodo and Yuh Sakata

    Version of Record online : 12 AUG 2011, DOI: 10.1111/j.1349-7006.2011.02030.x

  17. You have free access to this content
    Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice

    British Journal of Pharmacology

    Volume 171, Issue 9, May 2014, Pages: 2335–2350, R C P Lima-Júnior, H C Freitas, D V T Wong, C W S Wanderley, L G Nunes, L L Leite, S P Miranda, M H L P Souza, G A C Brito, P J C Magalhães, M M Teixeira, F Q Cunha and R A Ribeiro

    Version of Record online : 11 APR 2014, DOI: 10.1111/bph.12584

  18. Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells

    Journal of Pharmacy and Pharmacology

    Volume 64, Issue 5, May 2012, Pages: 727–734, Guang-Jian Du, Chong-Zhi Wang, Zhi-Yu Zhang, Xiao-Dong Wen, Jacqueline Somogyi, Tyler Calway, Tong-Chuan He, Wei Du and Chun-Su Yuan

    Version of Record online : 21 FEB 2012, DOI: 10.1111/j.2042-7158.2012.01463.x

  19. You have free access to this content
    Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo

    International Journal of Cancer

    Volume 73, Issue 5, 27 November 1997, Pages: 729–734, Sylvie Guichard, Daniel Cussac, Isabelle Hennebelle, Roland Bugat and Pierre Canal

    Version of Record online : 6 DEC 1998, DOI: 10.1002/(SICI)1097-0215(19971127)73:5<729::AID-IJC20>3.0.CO;2-#

  20. You have free access to this content
    Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells

    FEBS Letters

    Volume 581, Issue 8, April 17, 2007, Pages: 1649–1656, Dae Hwa Choi, Jin Sook Ha, Won Hyuck Lee, Jeong Kee Song, Gyu Yeol Kim, Jae Hoo Park, Hee Jeong Cha, Byung Ju Lee and Jeong Woo Park

    Version of Record online : 22 MAR 2007, DOI: 10.1016/j.febslet.2007.02.075